Última revisão: 1 Nov 2020
Última atualização: 11 Março 2020

Resumo

Definição

História e exame físico

Principais fatores de diagnóstico

  • presença de fatores de risco
  • estado mental alterado
  • rigidez muscular
  • disfunção autonômica
  • hipertermia
  • história psiquiátrica

Outros fatores de diagnóstico

  • história de deficiência de ferro
  • história de doença de Wilson

Fatores de risco

  • exposição a medicamentos antipsicóticos
  • supressão abrupta de medicamentos dopaminérgicos
  • anormalidade estrutural do cérebro
  • idade avançada
  • agitação preexistente
  • acatisia
  • sexo masculino
  • deficiência de ferro
  • catatonia
  • desidratação preexistente
  • exposição a antagonistas dopaminérgicos e outros antipsicóticos

Exames diagnósticos

1° exames a serem solicitados

  • Hemograma completo
  • creatina quinase sérica
  • perfil metabólico básico
  • tomografia computadorizada (TC) cranioencefálica
  • ressonância nuclear magnética (RNM) cranioencefálica
  • níveis de mioglobina e urinálise
  • urocultura
  • hemocultura
  • punção lombar
  • análise toxicológica
  • radiografia torácica
Mais 1° exames a serem solicitados

Algoritmo de tratamento

Colaboradores

Associate Professor

Harvard Medical School

Boston

MA

Divulgações

RJG is a member of the Neuroleptic Malignant Syndrome Professional Advisory Board, and has given expert testimony in medical malpractice tort claims in which NMS was alleged. He is an author of several references cited in this topic.

Dr Ronald J. Gurrera would like to gratefully acknowledge Dr Peter F. Buckley, a previous contributor to this topic. PFB is on the advisory board (a voluntary, uncompensated role) of the Neuroleptic Malignant Syndrome Information Service. He is also a consultant to Janssen Pharmaceutica and the National Institute of Mental Health (NIMH). He is conducting or has recently conducted research with funding support from AstraZeneca, NIMH, Janssen Pharmaceutica, Pfizer, Solvay, and Wyeth. Previous consultancy and research support has been from Abbott, Alamo Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Lundbeck, Janssen Pharmaceutica, Merck, NIMH, Roche Diagnostics, Pfizer, Solvay, and Wyeth. PFB has no patents or stock in any company. He is an author of several references cited in this topic. PFB is a co-investigator on a study also involving Dr John Lauriello and Dr Daniel R. Wilson, who were reviewers for this topic.

Colegas revisoresMOSTRAR TODOS

Consultant Psychiatrist

Honorary Senior Clinical Lecturer

Royal Cornhill Hospital

Aberdeen

UK

Divulgações

AH declares that she has no competing interests.

Professor and Chair

Department of Psychiatry

University of Missouri-Columbia

Columbia

MO

Divulgações

JL declares that he has no competing interests.

Assistant Professor

Department of Psychiatry

University of Missouri-Columbia

Columbia

MO

Divulgações

GG declares that he has no competing interests.

O uso deste conteúdo está sujeito aos nossos avisos legais